Regeneron, Sanofi to treat only 'critical' COVID-19 patients with arthritis drug

(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday they would test their arthritis drug, Kevzara, in critically ill COVID-19 patients after the drug showed no benefit for patients with a less severe form of the disease.The companies said the decision to discontinue testing for severe cases was based on the recommendation of an independent monitoring committee that reviewed early data from the trial.Early analysis of the study showed negative trends for most outcomes in..